Neumora Therapeutics price target lowered to $18 from $30 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Neumora Therapeutics (NMRA) to $18 from $30 and keeps a Buy rating on the shares. The firm says it understands investor disappointment that the KOASTAL-2 and -3 studies are not expected to readout until 2026, but in the end, it thinks the delays is “negligible and a small cost for improving the probability of success.”